On September 28, 2023, Hunan Xinlvfang Pharmaceutical Co., Ltd. organized a wonderful outdoor expansion activity to enhance team interaction and communication, and improve team cohesion and cooperation.
2023-09-28
2023 Fire Emergency Drill Report
To enhance company-wide fire safety awareness and improve employee response and self-protection capabilities in emergencies, and to ensure that every employee possesses a certain level of fire safety knowledge and eliminate fire hazards, the company invited Instructor Xiang Hao from Hunan Puan Fire Safety Publicity Center to conduct a company-wide fire safety training and emergency drill.
2023-07-13
Pharmaceutical raw materials and excipients are the foundation of drug production and directly affect the quality and efficacy of drugs. Therefore, their production must follow strict standards and regulations.
2022-07-28
Consulting on new trends and technological innovations in pharmaceutical R&D
With the rapid development of technology and deepening human understanding of diseases, the pharmaceutical R&D field is undergoing unprecedented changes. The following are some consulting contents about new trends and technological innovations in pharmaceutical R&D:
2022-01-10
What are the new trends in pharmaceutical research and development?
Personalized medicine and precision treatment: This is an important direction in pharmaceutical research, aiming to develop targeted drugs and treatment methods based on patients' specific indicators such as genes and proteins, in order to achieve precision treatment. With the development of genomics, proteomics and other technologies, personalized medicine and precision treatment have become hot topics in pharmaceutical research.
2021-11-12
To guide the research on changes in the pharmaceutics of already listed traditional Chinese medicines (TCMs) in China and provide a reference technical standard, the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has organized the formulation of the "Technical Guidelines for Research on Pharmaceutic Changes of Already Listed Traditional Chinese Medicines (Trial Implementation)" (see attachment). In accordance with the requirements of the "Notice on the Issuance of the Procedure for Issuing Technical Guidelines for Drugs" (Yaojian Zongyao Guan [2020] No. 9) issued by the Comprehensive Department of the NMPA, after review and approval by the NMPA, these guidelines are now released and come into effect from the date of release.
2021-07-09
In accordance with relevant regulations such as the "State Council's Opinion on Reforming the Drug and Medical Device Review and Approval System" (Guofa [2015] No. 44) and the "Regulations on Drug Registration Management" (Order No. 27 of the State Administration for Market Regulation), and to further implement the relevant requirements of drug review and approval reform and to advance the publicity of review information, the Center for Drug Evaluation (CDE) has, under the deployment of the National Medical Products Administration (NMPA), developed the "Work Standards for the Public Release of CDE Technical Review Reports (Trial Implementation)" (see attachment), which has been reviewed and approved by the NMPA and is hereby released and shall come into effect on June 1, 2021.
2021-07-09
Scan the QR code to contact online